BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33856509)

  • 21. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI.
    Yim JH; Kim YK; Min JH; Lee J; Kang TW; Lee SJ
    Abdom Radiol (NY); 2019 Jul; 44(7):2366-2376. PubMed ID: 30847566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification.
    Choi JY; Ha J; Choi SH; Kang HJ; Kim SY; Kim KW
    Abdom Radiol (NY); 2022 Mar; 47(3):1024-1031. PubMed ID: 35020008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS).
    Chernyak V; Fowler KJ; Heiken JP; Sirlin CB
    J Magn Reson Imaging; 2019 May; 49(5):1236-1252. PubMed ID: 30609194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?
    Pahade JK; Juice D; Staib L; Israel G; Cornfeld D; Mitchell K; Weinreb J
    Abdom Radiol (NY); 2016 Jul; 41(7):1270-84. PubMed ID: 26800701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis.
    Kim DW; Choi SH; Kim SY; Byun JH; Lee SS; Park SH; Kim KW
    Hepatol Int; 2020 Dec; 14(6):1009-1022. PubMed ID: 33146841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm.
    Lee CM; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Hepatol Int; 2021 Jun; 15(3):676-684. PubMed ID: 33956288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.
    Yoon JK; Han DH; Lee S; Choi JY; Choi GH; Kim DY; Kim MJ
    Cancer Res Treat; 2023 Jul; 55(3):939-947. PubMed ID: 36791769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging.
    Kang JH; Choi SH; Byun JH; Kim DH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur Radiol; 2020 May; 30(5):2881-2889. PubMed ID: 32020399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatobiliary agents and their role in LI-RADS.
    Hope TA; Fowler KJ; Sirlin CB; Costa EA; Yee J; Yeh BM; Heiken JP
    Abdom Imaging; 2015 Mar; 40(3):613-25. PubMed ID: 25287679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment.
    Rimola J; Davenport MS; Liu PS; Brown T; Marrero JA; McKenna BJ; Hussain HK
    Abdom Radiol (NY); 2019 Feb; 44(2):549-558. PubMed ID: 30218239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis.
    Pan J; Tao Y; Chi X; Yang L; Zhao Y; Chen F
    Eur Radiol; 2022 Aug; 32(8):5134-5143. PubMed ID: 35267090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
    Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
    Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
    J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.